Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT01502124
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis
Phase 1
Completed
- Conditions
- Chronic Kidney DiseaseEnd-Stage Renal DiseaseHealthy
- Interventions
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01502137
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, München, Germany
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenDelivery Systems
- Interventions
- Device: NordiFlex PenMate™
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT01500486
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
Observational Study of NovoNorm® in Subjects With Diabetes
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5841
- Registration Number
- NCT01498913
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30554
- Registration Number
- NCT01498900
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01498939
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Comparison of Two Insulin Detemir Formulations in Healthy Volunteers
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT01498926
Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT01497561
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Graz, Germany
Within-subject Variability of Insulin Detemir in Healthy Volunteers
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01497535
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01497587
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath